Family history of diabetes as a new determinant of insulin sensitivity and secretion in patients who have undergone a simultaneous pancreas-kidney transplant

Experimental and Clinical Transplantation

Volumn 8, Issue 1, 2010, Pages 29-37

  Rangel, Érika B ^a   Melaragno, Cláudio S ^a   Neves, Maria Deolinda F ^a   Dib, Sérgio A ^a   Gonzalez, Adriano M ^a   Linhares, Marcelo M ^a   Pacheco Silva, Álvaro ^a   Sá, João R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HOMA; Insulin secretion; Insulin sensitivity; Pancreas transplant

Indexed keywords

C PEPTIDE; GLUCOCORTICOID; GLUCOSE; INSULIN; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; BODY MASS; CELL FUNCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HOMEOSTASIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; KIDNEY TRANSPLANTATION; MALE; MODELS, BIOLOGICAL; PANCREAS TRANSPLANTATION; PEDIGREE; PREDNISONE; TACROLIMUS;

EID: 77749311342     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant. 2005;19(4):433-455.
2. Drachenberg CB, Papadimitriou JC, Farney A, et al. Pancreas transplantation: the histologic morphology of graft loss and clinical correlations. Transplantation. 2001;71(12):1784-1791.
3. Esmatjes E, Rodríguez-Villar C, Ricart MJ, et al. Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation. Transplantation. 1998;66(1):128-131.
4. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999;68(3):396-402.
5. Filler G, Neuschulz I, Vollmer I, Amendt P, Hocher B. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant. 2000;15(6):867-871.
6. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12(3):583-588.
7. Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation. 2001;72(10):1655-1661.
8. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13(1):221-227.
9. van Hooff JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2004 Dec;19 Suppl 6:vi8-vi12.
10. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Transplantation. 2003;75(suppl 10):S3-S24.
11. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(suppl 3):S16-S21.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
13. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495.
14. Costa A, Rios M, Casamitjana R, Gomis R, Conget I. High prevalence of abnormal glucose tolerance and metabolic disturbances in first degree relatives of NIDDM patients. A study in Catalonia, a Mediterranean community. Diabetes Res Clin Pract. 1998;41(3):191-196.
15. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25(7):1177-1184.
16. Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med. 2004;21(2):136-141.
17. Oterdoom LH, de Vries AP, van Son WJ, et al. Validation of insulin resistance indexes in a stable renal transplant population. Diabetes Care. 2005;28(10):2424-2429.
18. Perseghin G, Caumo A, Sereni LP, Battezzati A, Luzi L. Fasting blood sample-based assessment of insulin sensitivity in kidney-pancreas-transplanted patients. Diabetes Care. 2002;25(12):2207-2211.
19. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant. 2006;6(1):100-108.
20. Ghiringhello MT, Vieira JG, Tachibana TT, et al. Distribution of HOMAIR in Brazilian subjects with different body mass indexes. Arq Bras Endocrinol Metabol. 2006;50(3):573-574.
21. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004;4(10):1675-1683.
22. Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM. One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant. 2005;5(12):2922-2928.
23. Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005;5(11):2710-2718.
24. Christiansen E, Kjems LL, Vølund A, Tibell A, Binder C, Madsbad S. Insulin secretion rates estimated by two mathematical methods in pancreas-kidney transplant recipients. Am J Physiol. 1998;274(4 Pt 1):E716-E725.
25. Osei K, Cottrell DA, Henry ML, Tesi RJ, Ferguson RM, O'Dorisio TM. Minimal model analysis of insulin sensitivity and glucose-mediated glucose disposal in type 1 (insulin-dependent) diabetic pancreas allograft recipients. Diabetologia. 1992;35(7):676-680.
26. Hjelmesaeth J,Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care. 2001;24(12):2121-2126.
27. Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15(12):3233-3239.
28. Ekstrand AV. Effect of steroid-therapy on insulin sensitivity in insulin-dependent diabetic patients after kidney transplantation. J Diabet Complications. 1991;5(4):244-248.
29. Oterdoom LH, de Vries AP, Gansevoort RT, et al. Determinants of insulin resistance in renal transplant recipients. Transplantation. 2007;83(1):29-35.
30. Aguilera E, Recasens M, Flores L, et al. HOMA test in diabetic patients with simultaneous pancreas and kidney transplantation. Transplant Proc. 2002;34(1):206-208. Erratum in: Transplant Proc. 2002;34(6):2497-2498.
31. Boden G, Chen X, Ruiz J, Heifets M, Morris M, Badosa F. Insulin receptor down-regulation and impaired antilipolytic action of insulin in diabetic patients after pancreas/kidney transplantation. J Clin Endocrinol Metab. 1994;78(3):657-663.
32. Carpentier A, Patterson BW, Uffelman KD, et al. The effect of systemic versus portal insulin delivery in pancreas transplantation on insulin action and VLDL metabolism. Diabetes. 2001;50(6):1402-1413.
33. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2765-2775.
34. Gelens MA, Christiaans MH, van Hooff JP. Glucose metabolism before and after conversion from cyclosporine microemulsion to tacrolimus in stable renal recipients. Nephrol Dial Transplant. 2008;23(2):701-706.
35. Dmitrewski J, Krentz AJ, Mayer AD, et al. Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation. Diabetes Obes Metab. 2001;3(4):287-292.
36. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42(11):1663-1672.
37. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care. 1996;19(10):1138-1141.
38. Wagenknecht LE, Mayer EJ, Rewers M, et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol. 1995;5(6):464-472.
39. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46(1):3-19.
40. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE; American Diabetes Association GENNID Study Group. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes. 2002;51(7):2170-2178.
41. Cnop M, Vidal J, Hull RL, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care. 2007;30(3):677-682.
42. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787-794.
43. Hjelmesaeth J, Jenssen T, Hagen M, Egeland T, Hartmann A. Determinants of insulin secretion after renal transplantation. Metabolism. 2003;52(5):573-578.